High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine-an Observational Study in Adults from Ronneby, Sweden
By Axel G Andersson, Anna Lundgren, Yiyi Xu, Christel Nielsen, Christian H Lindh, Daniela Pineda, Julia Cederlund, Elisavet Pataridou, Sandra Søgaard Tøttenborg, Kajsa Ugelvig Petersen, Tony Fletcher, Martin Lagging, Mats Bemark, Kristina Jakobsson, and Ying Li
Environ Health Perspect
August 14, 2023
DOI: 10.1289/EHP11847
Background
Per- and polyfluoroalkyl substances (PFAS) are widely used, environmentally ubiquitous, and stable chemicals that have been associated with lower vaccine-induced antibody responses in children; however, data on adults are limited. The drinking water from one of the two waterworks in Ronneby, Sweden, was heavily contaminated for decades with PFAS from firefighting foams, primarily perfluorohexane sulfonic acid and perfluorooctanesulfonic acid (PFOS). Vaccination against SARS-CoV-2 offered a unique opportunity to investigate antibody responses to primary vaccination in adults who had been exposed to PFAS.
Objectives
Our objective was to evaluate associations between PFAS, across a wide range of exposure levels, and antibody responses in adults 5 wk and 6 months after a two-dose vaccination regime against SARS-CoV-2.
Methods
Adults age 20-60 y from Ronneby (, median PFOS serum level , fifth to 95th percentile ) and a group with background exposure (, median PFOS serum level ) received two doses of the Spikevax (Moderna) mRNA vaccine. The levels of seven PFAS were measured in serum before vaccination. Serum immunoglobulin G antibodies against the SARS-CoV-2 spike antigen (S-Abs) were measured before vaccination and at 5 wk () and 6 months () after the second vaccine dose. Linear regression analyses were fitted against current, historical, and prenatal exposure to PFAS, adjusting for sex, age, and smoking, excluding individuals with previous SARS-CoV-2-infection.
Results
PFAS exposure, regardless of how it was estimated, was not negatively associated with antibody levels 5 wk [current PFOS: S-Abs/PFOS interquartile range (IQR); 95% confidence interval (CI): , 7] or 6 months (current PFOS: 3% S-Abs/PFOS IQR; 95% CI: , 12) after COVID-19 vaccination.
Discussion
Following a strict study protocol, rigorous study design, and few dropouts, we found no indication that PFAS exposure negatively affected antibody responses to COVID-19 mRNA vaccination for up to 6 months after vaccination. https://doi.org/10.1289/EHP11847.
Topics: